Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | MTTP | P55157 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 3/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506829 | 0.75 | PDE10A (0.51) | SMOPDE10ARAB9ANPC1HSP90AA1 | |
| SCHEMBL6467142 | 0.72 | PDE10A (0.49) | PDE10ARAB9ANPC1 | |
| SCHEMBL10290992 | 0.72 | PDE10A (0.49) | SMOPDE10ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6561200 | 0.69 | DRD2 (0.52) | GRIN2BDRD2 | |
| SCHEMBL6255168 | 0.68 | GRIN2B (0.51) | GRIN2BDRD2FYN | |
| SCHEMBL4392502 | 0.68 | SMO (0.53) | SMOGRIN2BMTTPFYNSMN1; SMN2 | |
| SCHEMBL7909108 | 0.68 | SMO (0.53) | SMOGRIN2BMTTPFYNSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7906095 | 0.67 | SMO (0.53) | SMOGRIN2BMTTPFYN | |
| SCHEMBL14515547 | 0.66 | PSEN1 (0.40) | GRIN2BDRD2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6253652 | 0.66 | GRIN2B (0.44) | GRIN2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306149-A1 | USE OF BIARYLCARBOXAMIES IN THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-2010170-A2 | USE OF BIARYLCARBOXAMIDES IN THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120827-A2 | USE OF BIARYLCARBOXAMIDES IN THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306149-A1 | USE OF BIARYLCARBOXAMIES IN THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | GLI1, SHH, GLI2 | SMO 4/4885PDE10A 2955/4885GRIN2B 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.